Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Consolidated Net Income: 2017-2019

Historic Consolidated Net Income for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' Consolidated Net Income fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 31.04% down from last year.
  • Per Monopar Therapeutics' latest filing, its Consolidated Net Income stood at -$1.2 million for Q4 2019, which was down 61.29% from -$759,448 recorded in Q3 2019.
  • Monopar Therapeutics' 5-year Consolidated Net Income high stood at -$373,839 for Q1 2017, and its period low was -$14.9 million during Q3 2017.
  • Over the past 3 years, Monopar Therapeutics' median Consolidated Net Income value was -$828,354 (recorded in 2018), while the average stood at -$2.0 million.
  • Over the last 5 years, Monopar Therapeutics' Consolidated Net Income had its largest YoY gain of 95.52% in 2018, and its largest YoY loss of 140.01% in 2018.
  • Over the past 3 years, Monopar Therapeutics' Consolidated Net Income (Quarterly) stood at -$736,800 in 2017, then decreased by 25.73% to -$926,358 in 2018, then slumped by 32.23% to -$1.2 million in 2019.
  • Its Consolidated Net Income was -$1.2 million in Q4 2019, compared to -$759,448 in Q3 2019 and -$932,109 in Q2 2019.